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Figure S1. Gating strategy for flow cytometry analysis of αICAM and αPECAM antibody distributions 
among cell types in mouse lungs. A) Density plots showing cells localized to double-negative gate for 
unstained wild-type mouse lungs, to endothelial cell and double-negative gates for unstained TIE2-GFP 
mouse lungs, and to leukocyte, endothelial cell, and double-negative gates for TIE2-GFP mouse lungs 
stained with CD45 antibody. B) Density plots showing that all endothelial cells (as defined by gating in 
(A)) fall below negative-positive antibody fluorescence threshold in TIE2-GFP mice that don’t receive 
antibody. C) Density plots showing that all leukocytes (as defined by gating in (A)) fall below negative-




Figure S2. Two-step, site-specific radiolabeling technique using sortase A transpeptidation. Small 
peptide incorporating the radiometal chelating group, DOTA (1,4,7,10-tetrazacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid) was labeled with 111In and then attached by SrtA to the C-terminal end of 






Figure S3. Radiointernalization assay of αICAM and αPECAM affinity ligands. The percent of surface-
associated affinity ligand was determined by glycine elution after various periods of incubation at 37C. 
Internalization rates of monovalent and bivalent affinity ligands were compared on REN cells expressing 
the relevant target antigen and further compared to PmT mouse lung endothelial cells. In all cases, cells 
demonstrated similar, low rates of endocytosis of affinity ligands, with < 20% of internalized at 1 hour. 





Figure S4: Structure of Semi-physiologically based pharmacokinetic (PBPK) model.  (A) The proposed 
model structure links a 2-compartment mammillary model to a physiologically-based lung model.  The 
lung model is described using physiologically-relevant blood flow rates and volumes, as summarized in 
(B).  Within the lung space, protein is able to bind to target via estimated binding rate constants, pass 
into the interstitial space via bulk fluid flow, or return to the central compartment via lung blood flow 
rate.   
  
 
Figure S5: Model-fitted blood and lung concentration vs. time curves for untargeted IgG (A) and scFv 
(B) as well as Final Parameter Estimates for Untargeted IgG and scFv (C).  Symbols represent observed 




Figure S6: Blood and lung observed and model fitted concentration vs. time curves following a 5 μg 
dose of α ICAM (A) and α PECAM (B) mAbs. Final Parameter Estimates for Targeted mAbs (C). Symbols 




Figure S7: Blood and lung observed and model predicted concentration vs. time curves for α ICAM (A) 




Figure S8. Site specific modification of sTM and conjugation to DBCO-modified mAb.  A) Schematic 
showing sortase A modification of sTM-LPETGG – the enzyme removes the C-terminal FLAG tag and 
attaches a fluorescent, azidolysine containing peptide. B) SEC HPLC trace showing unpurified sTM 
reaction mixture (with excess peptide) and purified sTM-azide. C) HPLC trace of reactions of sTM-azide 
and mAb-DBCO at 1:3 molar ratio. A small excess of antibody produced the optimal amount of 1:1 
conjugate, which was subsequently purified by HPLC (black dotted lines). D and E) In vitro generation of 
APC by thrombin stimulated by ICAM- (D) and PECAM- (E) targeted TM conjugates. 
  
 
Figure S9: Model fitted concentration vs. time profiles for untargeted sTM conjugates.  Upper panel: 
IgG conjugates, Lower panel: scFv conjugates. Estimated parameters for untargeted sTM conjugates. 
Symbols represent observed data and solid lines represent model fitted profiles. 
  
 
Figure S10: Observed and model-predicted blood and lung concentration vs. time profiles for YN1-
sTM.  Upper panel: mAb conjugates, Lower panel: scFv conjugates. Symbols represent observed data 
and solid lines represent model fitted profiles. 
 
 
Figure S11: Observed and model-predicted blood and lung concentration vs. time curves for 390-sTM.  
Upper panel: mAb conjugates, Lower panel: scFv conjugates. Symbols represent observed data and 
solid lines represent model fitted profiles. 
  
Table S1. Characteristics of affinity ligands. Binding parameters (calculated Kd, nM), Blood and Lung 
concentrations (%ID/g), calculated values of circulation half-life (Hrs) and area under the lung 
concentration vs. time curve for monovalent vs bivalent affinity ligands to ICAM and PECAM. 
 
Table S2. Characteristics of TM conjugates. Binding parameters (calculated Kd, nM), Blood and Lung 
concentrations (%ID/g), calculated values of circulation half-life (Hrs) and area under the lung 
concentration vs. time curve for monovalent vs bivalent TM conjugates targeted to ICAM or PECAM. 
 
  
 Monovalent Bivalent 
PECAM-1 ICAM-1 Untargeted PECAM-1 ICAM-1 Untargeted 




30 min 2.5±0.2 3.5±0.8 1.9±0.4 10.6±0.13 7.4±0.4 28.9±3.0 
60 min 1±0.13 1±0.1 1.1±0.1 10.7±0.15 6.3±0.4 27.4±2.3 
120 
min 
0.4±0.1 0.24±0.03 0.7±0.07 8.9±0.15 6.7±0.6 25.7±1.9 
T ½ in blood, hrs 1.50 ± 0.24 0.984 ± 
0.153 




30 min 47.7±5.8 80.4±10.6 1.5±0.5 58.9±3.6 79.3±4.2 9.9±0.9 
60 min 13.4±1.7 11.4±1.71 - - - - 
120 
min 
11.5±0.8 4.8±0.9 0.6±0.1 37.3±2.8 60.1±2.1 7.8±1.0 
 180 
min 
8.9±0.8 4.0±0.7 0.4±0.04 - - - 
 360 
min 
- - - 30.5±0.3 60.9±2.1 8.6±0.6 
AUCinf lung 114±37 53.3±7.9 8.9±0.3 1023±507 1698±352 263±39 
 
 Monovalent Bivalent sTM azide ss 
PECAM-1 ICAM-1 Untargeted PECAM-1 ICAM-1 Untargeted   




30 min 9.9±1.2 4.1±0.4 8.2±0.8 2.2±0.1 2.1±0.3 4.8±2.0 10.4±0.5 2.0±0.6 
60 min 8.3±3.0 3.6±0.2 7.1±0.5 2.4±0.5 2.7±1.9 4.2±0.9 8.3±1.5 2.5±0.4 
120 min 6.7±2.6 2.7±0.1 5.8±0.6 1.9±0.4 2.7±0.5 3.2±0.5 8.5±0.6 1.8±0.6 




30 min 7.6±0.9 3.7±0.3 4.6±0.4 46.7±14.2 66.6±11.1 2.7±0.5 4.7±1.2 93.6±8.9 
60 min - - - 39.0±9.1 45.4±2.3 2.8±0.9  68±0.9 
120 min 5.8±2.2 2.1±0.4 2.8±0.3 20.3±7.9* 18.7±3.5 1.7±0.3 3.4±0.1 45.2±8.4 
AUCinf lung 34.7±19.9 12.4±4.2 14.5±1.9 188±90 141±3.2 11±1.5 46.6±10.8 253±18 
 
Table S3. Fold difference of AUCinf calculated for both affinity ligands and their corresponding 
conjugates.  
 
Table S4: Model-estimated binding parameters for scFv-sTM conjugates 
*Due to repeated convergence to binding parameters approaching 0.00 for both koff and for kon (<1x10-6), 
binding affinity was assumed to be negligible and values were fixed. 
Parameter YN1 (anti-ICAM) 390 (anti-PECAM) 
KD (nM) N.E.* 364 (41.4%) 
koff (h-1) 0.00 (FIX) 0.910 (85.7%) 
kon (nM-1h-1) 0.00 (FIX) 0.00250 (CALC) 
 
 
  Bivalent/Monovalent Mono/IgG Bivalent/IgG 
Affinity ligand ICAM 32 6 6.5 
 PECAM 8.9 12 4 
Conjugate  ICAM 12 (21) 0.9 12 
 PECAM 5.4 2.4 17 
 
